Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

Amit Bahl; Andrew Chilelli; Rita Faria; Nigel Rozario; Robert Snijder; Sari Stark; Axel S. Merseburger

doi:10.1007/s00345-025-06100-7

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

Amit Bahl^*
, Andrew Chilelli
, Rita Faria
, Nigel Rozario
, Robert Snijder
, Sari Stark
, Axel S. Merseburger

^*Corresponding author for this work

Department of Urology

University Hospitals Bristol NHS Foundation Trust
Astellas Pharma Europe Ltd

Original language	English
Article number	5
Journal	World Journal of Urology
Volume	44
Issue number	1
Pages (from-to)	5
ISSN	0724-4983
DOIs	https://doi.org/10.1007/s00345-025-06100-7
Publication status	Published - 01.2026

Funding

Funders
Astellas Pharma Inc.
Janssen Pharmaceutical Companies of Johnson & Johnson
Daria Renshaw
Astellas Pharma
ACCORD
AAA Pharmaceutical
Bayer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

DFG Research Classification Scheme

2.22-23 Reproductive Medicine, Urology

Access to Document

10.1007/s00345-025-06100-7

Cite this

Bahl, A., Chilelli, A., Faria, R., Rozario, N., Snijder, R., Stark, S., & Merseburger, A. S. (2026). Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. World Journal of Urology, 44(1), 5. Article 5. https://doi.org/10.1007/s00345-025-06100-7

Bahl, Amit ; Chilelli, Andrew ; Faria, Rita et al. / Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re : Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. In: World Journal of Urology. 2026 ; Vol. 44, No. 1. pp. 5.

@article{7163385bf1e74bd3be16ea1187d78da8,

title = "Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar{\textquoteright}s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9",

author = "Amit Bahl and Andrew Chilelli and Rita Faria and Nigel Rozario and Robert Snijder and Sari Stark and Merseburger, \{Axel S.\}",

year = "2026",

month = jan,

doi = "10.1007/s00345-025-06100-7",

language = "English",

volume = "44",

pages = "5",

journal = "World Journal of Urology",

issn = "0724-4983",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Bahl, A, Chilelli, A, Faria, R, Rozario, N, Snijder, R, Stark, S & Merseburger, AS 2026, 'Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9', World Journal of Urology, vol. 44, no. 1, 5, pp. 5. https://doi.org/10.1007/s00345-025-06100-7

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. / Bahl, Amit; Chilelli, Andrew; Faria, Rita et al.
In: World Journal of Urology, Vol. 44, No. 1, 5, 01.2026, p. 5.

Research output: Journal Articles › Letters › peer-review

TY - JOUR

T1 - Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re

T2 - Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

AU - Bahl, Amit

AU - Chilelli, Andrew

AU - Faria, Rita

AU - Rozario, Nigel

AU - Snijder, Robert

AU - Stark, Sari

AU - Merseburger, Axel S.

PY - 2026/1

Y1 - 2026/1

UR - https://www.scopus.com/pages/publications/105023232274

UR - https://www.mendeley.com/catalogue/122d42e7-211c-375f-8b30-bec14b243ef7/

U2 - 10.1007/s00345-025-06100-7

DO - 10.1007/s00345-025-06100-7

M3 - Letters

C2 - 41307573

AN - SCOPUS:105023232274

SN - 0724-4983

VL - 44

SP - 5

JO - World Journal of Urology

JF - World Journal of Urology

IS - 1

M1 - 5

ER -

Bahl A, Chilelli A, Faria R, Rozario N, Snijder R, Stark S et al. Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. World Journal of Urology. 2026 Jan;44(1):5. 5. doi: 10.1007/s00345-025-06100-7

Funding

UN SDGs

DFG Research Classification Scheme

Access to Document

Other files and links

Cite this